MicuRx Raises $55 Million for China-US Development of Novel Antibiotic

MicuRx Pharma, a San Francisco-Shanghai antibiotics company, closed a $55 million Series C financing from China investors. MicuRx said the money would be enough to complete clinical development of MRX-I in China and US, including a China filing for approval of the drug. MRX-1 is an oral, next-gen oxazolidinone antibacterial designed to combat drug-resistant infections. The C round was led by GP Healthcare Capital and joined by new investors GP TMT Capital, 3E Bioventures Capital and Delian Capital. More details.... Share this with colleagues: // //